Ahead of Incyte (INCY) Q4 Earnings: Get Ready With Wall Street Estimates for Key MetricsZacks Investment Research • 02/09/24
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)Business Wire • 02/05/24
Here are Wall Street's favorite stocks in the sector expected to grow profits the most in 2024Market Watch • 01/09/24
Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/08/24
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host DiseaseBusiness Wire • 12/10/23
Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual MeetingBusiness Wire • 11/02/23
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical ProgramsBusiness Wire • 10/31/23
Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023Business Wire • 10/16/23